<DOC>
	<DOCNO>NCT01250717</DOCNO>
	<brief_summary>The purpose research study determine combination chemotherapy hormone therapy safe helpful patient plan high-risk prostate cancer surgically remove . Some physician believe patient high risk cancer locate one area , may early small spread cancer outside prostate , perhaps even distant organ . Therefore , good treatment entire body need improve ability surgery local therapy cure prostate cancer . Since chemotherapy begin demonstrate increase activity advance prostate cancer patient , possible use chemotherapy combine hormonal therapy earlier course localize high risk patient might improve outcome patient .</brief_summary>
	<brief_title>Docetaxel Followed Radical Prostatectomy Patients With High Risk Localized Prostate Cancer</brief_title>
	<detailed_description>- Participants receive treatment outpatient clinic , docetaxel chemotherapy place bag fluid give vein every three week . Participants take Decadron ( dexamethasone ) mouth 12 hour 1 hour docetaxel 12 hour docetaxel . They also take estramustine casodex mouth home . Zoladex ( lupron ) give subcutaneously ( skin ) 4 time every three month . They also start coumadin begin time first docetaxel infusion continue 3 week 4th cycle chemotherapy . - After 2 month ( cycle ) therapy , participant evaluate order ass response toxicity treatment , include review medical history , physical examination , blood test , include PSA . If evidence progression excessive toxicity , treatment continue 2 month manner . - At end 4 month chemotherapy , participant reassess medical oncologist urologist regard surgery remove prostate .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate Potential candidate radical prostatectomy Any following : ) clinical stage T3 patient , b ) Serum PSA great equal 20 ng/ml , c ) Gleason score 810 , ) Clinical T2 disease either MRI evidence seminal vesicle involvement Gleason 4+3 cancer either 5 6 biopsy positive ECOG Performance Status 01 WBC &gt; 3,000 ul HCT &gt; 30 % PLT &gt; 100,000/ul LFTS within normal limit Prior hormone , radiation chemotherapy prostate cancer Myocardial infarction within 1 year , significant change anginal pattern within last 6 month , current congestive heart failure ( NYHA Class 2 high ) , deep venous thrombosis within 1 year Evidence active infection Significant peripheral neuropathy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>prostatectomy</keyword>
	<keyword>docetaxel</keyword>
</DOC>